nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0782	0.225	CbGbCtD
Ziprasidone—CYP3A7—Ifosfamide—testicular cancer	0.0782	0.225	CbGbCtD
Ziprasidone—CYP3A5—Ifosfamide—testicular cancer	0.0586	0.168	CbGbCtD
Ziprasidone—ADRA1B—vas deferens—testicular cancer	0.0485	0.288	CbGeAlD
Ziprasidone—HTR7—vas deferens—testicular cancer	0.0282	0.168	CbGeAlD
Ziprasidone—CYP3A5—Etoposide—testicular cancer	0.028	0.0805	CbGbCtD
Ziprasidone—CYP3A4—Ifosfamide—testicular cancer	0.0229	0.0657	CbGbCtD
Ziprasidone—CYP1A2—Etoposide—testicular cancer	0.0209	0.0599	CbGbCtD
Ziprasidone—CYP2D6—Vinblastine—testicular cancer	0.0191	0.0548	CbGbCtD
Ziprasidone—H1F0—semen—testicular cancer	0.0163	0.0969	CbGeAlD
Ziprasidone—CYP3A4—Vinblastine—testicular cancer	0.0121	0.0348	CbGbCtD
Ziprasidone—HTR7—vein—testicular cancer	0.012	0.0713	CbGeAlD
Ziprasidone—CYP2D6—Doxorubicin—testicular cancer	0.0117	0.0337	CbGbCtD
Ziprasidone—CYP3A4—Etoposide—testicular cancer	0.0109	0.0314	CbGbCtD
Ziprasidone—HTR2A—vein—testicular cancer	0.00748	0.0445	CbGeAlD
Ziprasidone—CYP3A4—Doxorubicin—testicular cancer	0.00745	0.0214	CbGbCtD
Ziprasidone—H1F0—embryo—testicular cancer	0.00368	0.0219	CbGeAlD
Ziprasidone—DRD4—testis—testicular cancer	0.00353	0.021	CbGeAlD
Ziprasidone—H1F0—seminal vesicle—testicular cancer	0.00346	0.0205	CbGeAlD
Ziprasidone—HTR1E—female gonad—testicular cancer	0.00343	0.0204	CbGeAlD
Ziprasidone—CHRM4—testis—testicular cancer	0.00267	0.0159	CbGeAlD
Ziprasidone—DRD5—female gonad—testicular cancer	0.00262	0.0156	CbGeAlD
Ziprasidone—H1F0—gonad—testicular cancer	0.0025	0.0148	CbGeAlD
Ziprasidone—H1F0—female gonad—testicular cancer	0.00203	0.0121	CbGeAlD
Ziprasidone—KCNH2—seminal vesicle—testicular cancer	0.00199	0.0118	CbGeAlD
Ziprasidone—ADRA2C—seminal vesicle—testicular cancer	0.00196	0.0116	CbGeAlD
Ziprasidone—H1F0—testis—testicular cancer	0.0018	0.0107	CbGeAlD
Ziprasidone—ADRA2A—seminal vesicle—testicular cancer	0.00156	0.00929	CbGeAlD
Ziprasidone—HTR7—gonad—testicular cancer	0.00154	0.00916	CbGeAlD
Ziprasidone—HTR2A—embryo—testicular cancer	0.00142	0.00841	CbGeAlD
Ziprasidone—CHRM3—female gonad—testicular cancer	0.00132	0.00782	CbGeAlD
Ziprasidone—H1F0—lymph node—testicular cancer	0.00131	0.00775	CbGeAlD
Ziprasidone—CHRM3—testis—testicular cancer	0.00117	0.00693	CbGeAlD
Ziprasidone—KCNH2—female gonad—testicular cancer	0.00117	0.00693	CbGeAlD
Ziprasidone—ADRA2C—female gonad—testicular cancer	0.00115	0.00684	CbGeAlD
Ziprasidone—ADRA2A—gonad—testicular cancer	0.00113	0.00672	CbGeAlD
Ziprasidone—HTR7—testis—testicular cancer	0.00111	0.0066	CbGeAlD
Ziprasidone—DRD2—testis—testicular cancer	0.00105	0.00624	CbGeAlD
Ziprasidone—KCNH2—testis—testicular cancer	0.00104	0.00615	CbGeAlD
Ziprasidone—ADRA2C—testis—testicular cancer	0.00102	0.00607	CbGeAlD
Ziprasidone—CYP3A5—female gonad—testicular cancer	0.000964	0.00572	CbGeAlD
Ziprasidone—HTR2A—gonad—testicular cancer	0.000961	0.00571	CbGeAlD
Ziprasidone—HRH1—female gonad—testicular cancer	0.000936	0.00556	CbGeAlD
Ziprasidone—ADRA2A—female gonad—testicular cancer	0.000919	0.00546	CbGeAlD
Ziprasidone—HRH1—testis—testicular cancer	0.00083	0.00493	CbGeAlD
Ziprasidone—ADRA2A—testis—testicular cancer	0.000815	0.00484	CbGeAlD
Ziprasidone—KCNH2—lymph node—testicular cancer	0.00075	0.00446	CbGeAlD
Ziprasidone—ADRA2C—lymph node—testicular cancer	0.00074	0.0044	CbGeAlD
Ziprasidone—CYP2D6—female gonad—testicular cancer	0.000712	0.00423	CbGeAlD
Ziprasidone—HTR2A—testis—testicular cancer	0.000693	0.00412	CbGeAlD
Ziprasidone—CYP2D6—testis—testicular cancer	0.000631	0.00375	CbGeAlD
Ziprasidone—HRH1—lymph node—testicular cancer	0.000601	0.00357	CbGeAlD
Ziprasidone—ADRA2A—lymph node—testicular cancer	0.000591	0.00351	CbGeAlD
Ziprasidone—Urinary tract disorder—Methotrexate—testicular cancer	0.000232	0.000497	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000232	0.000497	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—testicular cancer	0.000231	0.000495	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—testicular cancer	0.000231	0.000495	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—testicular cancer	0.00023	0.000493	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—testicular cancer	0.00023	0.000492	CcSEcCtD
Ziprasidone—Feeling abnormal—Etoposide—testicular cancer	0.000229	0.000492	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—testicular cancer	0.000229	0.000491	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—testicular cancer	0.000228	0.00049	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—testicular cancer	0.000228	0.000488	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Etoposide—testicular cancer	0.000228	0.000488	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—testicular cancer	0.000226	0.000485	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—testicular cancer	0.000226	0.000485	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—testicular cancer	0.000226	0.000485	CcSEcCtD
Ziprasidone—Vomiting—Ifosfamide—testicular cancer	0.000224	0.00048	CcSEcCtD
Ziprasidone—Hypersensitivity—Cisplatin—testicular cancer	0.000224	0.00048	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—testicular cancer	0.000224	0.000479	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—testicular cancer	0.000222	0.000477	CcSEcCtD
Ziprasidone—Rash—Ifosfamide—testicular cancer	0.000222	0.000476	CcSEcCtD
Ziprasidone—Dermatitis—Ifosfamide—testicular cancer	0.000222	0.000476	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000222	0.000476	CcSEcCtD
Ziprasidone—Urticaria—Etoposide—testicular cancer	0.000221	0.000474	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—testicular cancer	0.000221	0.000473	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—testicular cancer	0.000221	0.000473	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—testicular cancer	0.00022	0.000472	CcSEcCtD
Ziprasidone—Abdominal pain—Etoposide—testicular cancer	0.00022	0.000472	CcSEcCtD
Ziprasidone—Body temperature increased—Etoposide—testicular cancer	0.00022	0.000472	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—testicular cancer	0.00022	0.000472	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—testicular cancer	0.00022	0.000471	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—testicular cancer	0.00022	0.000471	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—testicular cancer	0.000219	0.00047	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—testicular cancer	0.000219	0.000469	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—testicular cancer	0.000218	0.000468	CcSEcCtD
Ziprasidone—Asthenia—Cisplatin—testicular cancer	0.000218	0.000467	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—testicular cancer	0.000218	0.000467	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—testicular cancer	0.000218	0.000467	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—testicular cancer	0.000217	0.000465	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—testicular cancer	0.000217	0.000465	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—testicular cancer	0.000216	0.000464	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—testicular cancer	0.000216	0.000463	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—testicular cancer	0.000216	0.000463	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—testicular cancer	0.000215	0.000462	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—testicular cancer	0.000213	0.000458	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—testicular cancer	0.000213	0.000456	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—testicular cancer	0.000212	0.000454	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—testicular cancer	0.000212	0.000454	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—testicular cancer	0.000211	0.000453	CcSEcCtD
Ziprasidone—Chills—Methotrexate—testicular cancer	0.000211	0.000451	CcSEcCtD
Ziprasidone—Nausea—Ifosfamide—testicular cancer	0.000209	0.000449	CcSEcCtD
Ziprasidone—Diarrhoea—Cisplatin—testicular cancer	0.000208	0.000446	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—testicular cancer	0.000207	0.000445	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—testicular cancer	0.000207	0.000443	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—testicular cancer	0.000206	0.000441	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—testicular cancer	0.000205	0.00044	CcSEcCtD
Ziprasidone—Hypersensitivity—Etoposide—testicular cancer	0.000205	0.00044	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—testicular cancer	0.000205	0.000439	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—testicular cancer	0.000204	0.000438	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—testicular cancer	0.000204	0.000438	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—testicular cancer	0.000204	0.000438	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—testicular cancer	0.000204	0.000437	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—testicular cancer	0.000204	0.000437	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—testicular cancer	0.000203	0.000436	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—testicular cancer	0.000203	0.000436	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—testicular cancer	0.000202	0.000433	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—testicular cancer	0.000202	0.000432	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—testicular cancer	0.000201	0.00043	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—testicular cancer	0.0002	0.000429	CcSEcCtD
Ziprasidone—Asthenia—Etoposide—testicular cancer	0.0002	0.000428	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—testicular cancer	0.0002	0.000428	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—testicular cancer	0.000199	0.000427	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—testicular cancer	0.000199	0.000427	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—testicular cancer	0.000198	0.000425	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—testicular cancer	0.000198	0.000424	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—testicular cancer	0.000198	0.000424	CcSEcCtD
Ziprasidone—Chills—Epirubicin—testicular cancer	0.000197	0.000422	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—testicular cancer	0.000196	0.000421	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—testicular cancer	0.000196	0.00042	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—testicular cancer	0.000194	0.000416	CcSEcCtD
Ziprasidone—Vomiting—Cisplatin—testicular cancer	0.000193	0.000414	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—testicular cancer	0.000193	0.000413	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—testicular cancer	0.000192	0.000412	CcSEcCtD
Ziprasidone—Rash—Cisplatin—testicular cancer	0.000192	0.000411	CcSEcCtD
Ziprasidone—Dermatitis—Cisplatin—testicular cancer	0.000191	0.00041	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—testicular cancer	0.000191	0.00041	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—testicular cancer	0.000191	0.00041	CcSEcCtD
Ziprasidone—Diarrhoea—Etoposide—testicular cancer	0.00019	0.000408	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—testicular cancer	0.00019	0.000407	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—testicular cancer	0.000189	0.000406	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—testicular cancer	0.000189	0.000405	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—testicular cancer	0.000189	0.000404	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—testicular cancer	0.000188	0.000404	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—testicular cancer	0.000185	0.000396	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—testicular cancer	0.000184	0.000395	CcSEcCtD
Ziprasidone—Dizziness—Etoposide—testicular cancer	0.000184	0.000395	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—testicular cancer	0.000184	0.000394	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—testicular cancer	0.000184	0.000393	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—testicular cancer	0.000184	0.000393	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000183	0.000393	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—testicular cancer	0.000183	0.000392	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—testicular cancer	0.000182	0.000391	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—testicular cancer	0.000182	0.000389	CcSEcCtD
Ziprasidone—Nausea—Cisplatin—testicular cancer	0.00018	0.000387	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—testicular cancer	0.00018	0.000386	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—testicular cancer	0.00018	0.000385	CcSEcCtD
Ziprasidone—Cough—Methotrexate—testicular cancer	0.000178	0.000382	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—testicular cancer	0.000178	0.000382	CcSEcCtD
Ziprasidone—Vomiting—Etoposide—testicular cancer	0.000177	0.000379	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—testicular cancer	0.000177	0.000379	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—testicular cancer	0.000177	0.000379	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—testicular cancer	0.000177	0.000379	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—testicular cancer	0.000176	0.000377	CcSEcCtD
Ziprasidone—Rash—Etoposide—testicular cancer	0.000175	0.000376	CcSEcCtD
Ziprasidone—Dermatitis—Etoposide—testicular cancer	0.000175	0.000376	CcSEcCtD
Ziprasidone—Headache—Etoposide—testicular cancer	0.000174	0.000374	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—testicular cancer	0.000174	0.000374	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—testicular cancer	0.000174	0.000373	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—testicular cancer	0.000174	0.000373	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—testicular cancer	0.000174	0.000373	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000173	0.00037	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—testicular cancer	0.000172	0.000368	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—testicular cancer	0.000171	0.000368	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—testicular cancer	0.000171	0.000367	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—testicular cancer	0.000171	0.000367	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—testicular cancer	0.00017	0.000365	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—testicular cancer	0.000169	0.000362	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—testicular cancer	0.000168	0.00036	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—testicular cancer	0.000168	0.00036	CcSEcCtD
Ziprasidone—Cough—Epirubicin—testicular cancer	0.000167	0.000358	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—testicular cancer	0.000167	0.000357	CcSEcCtD
Ziprasidone—Infection—Methotrexate—testicular cancer	0.000166	0.000355	CcSEcCtD
Ziprasidone—Nausea—Etoposide—testicular cancer	0.000165	0.000354	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—testicular cancer	0.000165	0.000354	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—testicular cancer	0.000163	0.000351	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—testicular cancer	0.000163	0.000351	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—testicular cancer	0.000163	0.00035	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—testicular cancer	0.000163	0.000349	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—testicular cancer	0.000163	0.000349	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—testicular cancer	0.000163	0.000349	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—testicular cancer	0.000163	0.000348	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—testicular cancer	0.000162	0.000348	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—testicular cancer	0.000162	0.000347	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000162	0.000347	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—testicular cancer	0.000161	0.000346	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—testicular cancer	0.000159	0.000341	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—testicular cancer	0.000159	0.000341	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—testicular cancer	0.000159	0.000341	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—testicular cancer	0.000159	0.00034	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—testicular cancer	0.000158	0.000339	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—testicular cancer	0.000157	0.000337	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—testicular cancer	0.000156	0.000335	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—testicular cancer	0.000156	0.000334	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—testicular cancer	0.000155	0.000333	CcSEcCtD
Ziprasidone—Infection—Epirubicin—testicular cancer	0.000155	0.000332	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—testicular cancer	0.000154	0.000331	CcSEcCtD
Ziprasidone—Shock—Epirubicin—testicular cancer	0.000153	0.000329	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—testicular cancer	0.000153	0.000328	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—testicular cancer	0.000153	0.000328	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—testicular cancer	0.000153	0.000327	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—testicular cancer	0.000152	0.000326	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000152	0.000326	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—testicular cancer	0.000152	0.000325	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—testicular cancer	0.000151	0.000323	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—testicular cancer	0.000151	0.000323	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—testicular cancer	0.000151	0.000323	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—testicular cancer	0.000151	0.000323	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—testicular cancer	0.000151	0.000323	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—testicular cancer	0.00015	0.000322	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—testicular cancer	0.00015	0.000321	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00015	0.000321	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—testicular cancer	0.000149	0.000319	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—testicular cancer	0.000149	0.000319	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—testicular cancer	0.000148	0.000318	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—testicular cancer	0.000147	0.000316	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—testicular cancer	0.000147	0.000315	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—testicular cancer	0.000146	0.000313	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—testicular cancer	0.000146	0.000312	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—testicular cancer	0.000145	0.000311	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000144	0.000309	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—testicular cancer	0.000144	0.000308	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—testicular cancer	0.000143	0.000307	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000142	0.000305	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—testicular cancer	0.000142	0.000304	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—testicular cancer	0.000142	0.000304	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—testicular cancer	0.000141	0.000303	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—testicular cancer	0.000141	0.000303	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—testicular cancer	0.000141	0.000302	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—testicular cancer	0.00014	0.000301	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—testicular cancer	0.00014	0.0003	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—testicular cancer	0.00014	0.000299	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—testicular cancer	0.000139	0.000298	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—testicular cancer	0.000139	0.000297	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—testicular cancer	0.000138	0.000295	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—testicular cancer	0.000137	0.000295	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—testicular cancer	0.000137	0.000294	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000136	0.000292	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—testicular cancer	0.000136	0.000291	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—testicular cancer	0.000135	0.000289	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000135	0.000289	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—testicular cancer	0.000135	0.000288	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—testicular cancer	0.000133	0.000286	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—testicular cancer	0.000132	0.000284	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—testicular cancer	0.000132	0.000283	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—testicular cancer	0.000132	0.000283	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000132	0.000282	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—testicular cancer	0.000131	0.00028	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—testicular cancer	0.00013	0.000278	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—testicular cancer	0.000129	0.000276	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—testicular cancer	0.000129	0.000276	CcSEcCtD
Ziprasidone—ADRA1A—AMPK Signaling—STK11—testicular cancer	0.000128	0.00746	CbGpPWpGaD
Ziprasidone—Somnolence—Doxorubicin—testicular cancer	0.000128	0.000275	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000128	0.000274	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—testicular cancer	0.000127	0.000272	CcSEcCtD
Ziprasidone—DRD1—GPCR ligand binding—INSL3—testicular cancer	0.000126	0.00732	CbGpPWpGaD
Ziprasidone—Decreased appetite—Doxorubicin—testicular cancer	0.000125	0.000269	CcSEcCtD
Ziprasidone—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000125	0.00729	CbGpPWpGaD
Ziprasidone—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000125	0.00726	CbGpPWpGaD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000125	0.000267	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—testicular cancer	0.000124	0.000267	CcSEcCtD
Ziprasidone—DRD3—GPCR ligand binding—INSL3—testicular cancer	0.000124	0.00723	CbGpPWpGaD
Ziprasidone—Urticaria—Epirubicin—testicular cancer	0.000124	0.000266	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—testicular cancer	0.000123	0.000265	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—testicular cancer	0.000123	0.000264	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—testicular cancer	0.000123	0.000264	CcSEcCtD
Ziprasidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000123	0.00714	CbGpPWpGaD
Ziprasidone—Hypersensitivity—Methotrexate—testicular cancer	0.000123	0.000263	CcSEcCtD
Ziprasidone—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000123	0.00713	CbGpPWpGaD
Ziprasidone—CHRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000122	0.00711	CbGpPWpGaD
Ziprasidone—CHRM3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000122	0.00708	CbGpPWpGaD
Ziprasidone—HTR1E—GPCR downstream signaling—INSL3—testicular cancer	0.000121	0.00704	CbGpPWpGaD
Ziprasidone—CHRM2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000121	0.00701	CbGpPWpGaD
Ziprasidone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00012	0.007	CbGpPWpGaD
Ziprasidone—Asthenia—Methotrexate—testicular cancer	0.00012	0.000256	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—testicular cancer	0.000119	0.000255	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000118	0.000253	CcSEcCtD
Ziprasidone—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000117	0.00682	CbGpPWpGaD
Ziprasidone—Hypersensitivity—Epirubicin—testicular cancer	0.000115	0.000246	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—testicular cancer	0.000115	0.000246	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—testicular cancer	0.000114	0.000245	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—testicular cancer	0.000114	0.000245	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—testicular cancer	0.000114	0.000245	CcSEcCtD
Ziprasidone—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.000112	0.00652	CbGpPWpGaD
Ziprasidone—Asthenia—Epirubicin—testicular cancer	0.000112	0.00024	CcSEcCtD
Ziprasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000112	0.0065	CbGpPWpGaD
Ziprasidone—Dizziness—Methotrexate—testicular cancer	0.00011	0.000236	CcSEcCtD
Ziprasidone—HTR1E—Signaling by GPCR—INSL3—testicular cancer	0.00011	0.00639	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR ligand binding—INSL3—testicular cancer	0.000108	0.0063	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR ligand binding—INSL3—testicular cancer	0.000108	0.00626	CbGpPWpGaD
Ziprasidone—DRD5—GPCR downstream signaling—INSL3—testicular cancer	0.000107	0.00623	CbGpPWpGaD
Ziprasidone—Diarrhoea—Epirubicin—testicular cancer	0.000107	0.000229	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—testicular cancer	0.000106	0.000228	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—testicular cancer	0.000106	0.000227	CcSEcCtD
Ziprasidone—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.000106	0.00615	CbGpPWpGaD
Ziprasidone—Rash—Methotrexate—testicular cancer	0.000105	0.000225	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—testicular cancer	0.000105	0.000225	CcSEcCtD
Ziprasidone—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000105	0.00609	CbGpPWpGaD
Ziprasidone—Headache—Methotrexate—testicular cancer	0.000104	0.000224	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—testicular cancer	0.000104	0.000222	CcSEcCtD
Ziprasidone—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	0.000103	0.006	CbGpPWpGaD
Ziprasidone—Dizziness—Epirubicin—testicular cancer	0.000103	0.000221	CcSEcCtD
Ziprasidone—CYP3A7—Biological oxidations—HPGDS—testicular cancer	0.0001	0.00583	CbGpPWpGaD
Ziprasidone—Vomiting—Epirubicin—testicular cancer	9.92e-05	0.000213	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—testicular cancer	9.9e-05	0.000212	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—testicular cancer	9.88e-05	0.000212	CcSEcCtD
Ziprasidone—Rash—Epirubicin—testicular cancer	9.84e-05	0.000211	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—testicular cancer	9.83e-05	0.000211	CcSEcCtD
Ziprasidone—Headache—Epirubicin—testicular cancer	9.77e-05	0.00021	CcSEcCtD
Ziprasidone—DRD5—Signaling by GPCR—INSL3—testicular cancer	9.74e-05	0.00566	CbGpPWpGaD
Ziprasidone—Dizziness—Doxorubicin—testicular cancer	9.55e-05	0.000205	CcSEcCtD
Ziprasidone—DRD2—GPCR ligand binding—INSL3—testicular cancer	9.52e-05	0.00553	CbGpPWpGaD
Ziprasidone—CHRM3—Integration of energy metabolism—STK11—testicular cancer	9.37e-05	0.00544	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR ligand binding—INSL3—testicular cancer	9.37e-05	0.00544	CbGpPWpGaD
Ziprasidone—HRH1—GPCR ligand binding—INSL3—testicular cancer	9.35e-05	0.00543	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR ligand binding—INSL3—testicular cancer	9.32e-05	0.00541	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR ligand binding—INSL3—testicular cancer	9.29e-05	0.00539	CbGpPWpGaD
Ziprasidone—Nausea—Epirubicin—testicular cancer	9.27e-05	0.000199	CcSEcCtD
Ziprasidone—CHRM2—GPCR ligand binding—INSL3—testicular cancer	9.2e-05	0.00534	CbGpPWpGaD
Ziprasidone—Vomiting—Doxorubicin—testicular cancer	9.18e-05	0.000197	CcSEcCtD
Ziprasidone—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	9.17e-05	0.00533	CbGpPWpGaD
Ziprasidone—Rash—Doxorubicin—testicular cancer	9.1e-05	0.000195	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—testicular cancer	9.09e-05	0.000195	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—testicular cancer	9.04e-05	0.000194	CcSEcCtD
Ziprasidone—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	8.6e-05	0.00499	CbGpPWpGaD
Ziprasidone—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	8.6e-05	0.00499	CbGpPWpGaD
Ziprasidone—Nausea—Doxorubicin—testicular cancer	8.57e-05	0.000184	CcSEcCtD
Ziprasidone—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	8.52e-05	0.00495	CbGpPWpGaD
Ziprasidone—HTR6—GPCR downstream signaling—INSL3—testicular cancer	8.28e-05	0.00481	CbGpPWpGaD
Ziprasidone—HTR7—GPCR downstream signaling—INSL3—testicular cancer	8.27e-05	0.0048	CbGpPWpGaD
Ziprasidone—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	8.21e-05	0.00477	CbGpPWpGaD
Ziprasidone—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	8.04e-05	0.00467	CbGpPWpGaD
Ziprasidone—DRD4—GPCR downstream signaling—INSL3—testicular cancer	7.91e-05	0.0046	CbGpPWpGaD
Ziprasidone—CHRM4—GPCR downstream signaling—INSL3—testicular cancer	7.81e-05	0.00454	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—INSL3—testicular cancer	7.52e-05	0.00437	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—INSL3—testicular cancer	7.51e-05	0.00436	CbGpPWpGaD
Ziprasidone—CHRM5—GPCR downstream signaling—INSL3—testicular cancer	7.48e-05	0.00434	CbGpPWpGaD
Ziprasidone—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	7.47e-05	0.00434	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—INSL3—testicular cancer	7.46e-05	0.00433	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—INSL3—testicular cancer	7.3e-05	0.00424	CbGpPWpGaD
Ziprasidone—CYP3A5—Biological oxidations—HPGDS—testicular cancer	7.25e-05	0.00421	CbGpPWpGaD
Ziprasidone—CHRM4—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	7.19e-05	0.00418	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—INSL3—testicular cancer	7.19e-05	0.00417	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—INSL3—testicular cancer	7.13e-05	0.00414	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—INSL3—testicular cancer	7.09e-05	0.00412	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—INSL3—testicular cancer	7.03e-05	0.00408	CbGpPWpGaD
Ziprasidone—CHRM5—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	6.89e-05	0.004	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—INSL3—testicular cancer	6.79e-05	0.00394	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—INSL3—testicular cancer	6.5e-05	0.00378	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—INSL3—testicular cancer	6.47e-05	0.00376	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—INSL3—testicular cancer	6.38e-05	0.00371	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	6.35e-05	0.00369	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	6.13e-05	0.00356	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	6.1e-05	0.00354	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	5.93e-05	0.00344	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	5.83e-05	0.00339	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	5.76e-05	0.00335	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—INSL3—testicular cancer	5.75e-05	0.00334	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—INSL3—testicular cancer	5.56e-05	0.00323	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—INSL3—testicular cancer	5.54e-05	0.00322	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	5.38e-05	0.00313	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—INSL3—testicular cancer	5.38e-05	0.00312	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	5.3e-05	0.00308	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	5.29e-05	0.00307	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—INSL3—testicular cancer	5.28e-05	0.00307	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	5.26e-05	0.00306	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—INSL3—testicular cancer	5.25e-05	0.00305	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	5.2e-05	0.00302	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	5.18e-05	0.00301	CbGpPWpGaD
Ziprasidone—CYP2D6—Biological oxidations—HPGDS—testicular cancer	5.16e-05	0.00299	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—INSL3—testicular cancer	4.89e-05	0.00284	CbGpPWpGaD
Ziprasidone—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	4.85e-05	0.00282	CbGpPWpGaD
Ziprasidone—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	4.83e-05	0.00281	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	4.82e-05	0.0028	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—INSL3—testicular cancer	4.81e-05	0.00279	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—INSL3—testicular cancer	4.8e-05	0.00279	CbGpPWpGaD
Ziprasidone—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	4.79e-05	0.00278	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—INSL3—testicular cancer	4.78e-05	0.00278	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—INSL3—testicular cancer	4.77e-05	0.00277	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—INSL3—testicular cancer	4.72e-05	0.00274	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	4.71e-05	0.00273	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—INSL3—testicular cancer	4.44e-05	0.00258	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—INSL3—testicular cancer	4.44e-05	0.00258	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—INSL3—testicular cancer	4.41e-05	0.00256	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	4.37e-05	0.00254	CbGpPWpGaD
Ziprasidone—CYP1A2—Biological oxidations—HPGDS—testicular cancer	4.37e-05	0.00254	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—INSL3—testicular cancer	4.31e-05	0.00251	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—INSL3—testicular cancer	4.25e-05	0.00247	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—INSL3—testicular cancer	4.19e-05	0.00243	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—INSL3—testicular cancer	4.01e-05	0.00233	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—INSL3—testicular cancer	3.82e-05	0.00222	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—INSL3—testicular cancer	3.77e-05	0.00219	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—INSL3—testicular cancer	3.4e-05	0.00198	CbGpPWpGaD
Ziprasidone—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.37e-05	0.00196	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—INSL3—testicular cancer	3.29e-05	0.00191	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—INSL3—testicular cancer	3.27e-05	0.0019	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—INSL3—testicular cancer	3.18e-05	0.00185	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—INSL3—testicular cancer	3.13e-05	0.00182	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—INSL3—testicular cancer	2.89e-05	0.00168	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—INSL3—testicular cancer	2.84e-05	0.00165	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—INSL3—testicular cancer	2.83e-05	0.00165	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—INSL3—testicular cancer	2.82e-05	0.00164	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—INSL3—testicular cancer	2.82e-05	0.00164	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—INSL3—testicular cancer	2.79e-05	0.00162	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—INSL3—testicular cancer	2.78e-05	0.00161	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—INSL3—testicular cancer	2.58e-05	0.0015	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—H2AFZ—testicular cancer	2.08e-05	0.00121	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—STK11—testicular cancer	2.07e-05	0.0012	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—KITLG—testicular cancer	1.91e-05	0.00111	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—H2AFZ—testicular cancer	1.84e-05	0.00107	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—STK11—testicular cancer	1.83e-05	0.00106	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—HPGDS—testicular cancer	1.72e-05	0.000996	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—KITLG—testicular cancer	1.69e-05	0.000984	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.68e-05	0.000974	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—HPGDS—testicular cancer	1.67e-05	0.000968	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—HPGDS—testicular cancer	1.47e-05	0.000857	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—FGFR3—testicular cancer	1.42e-05	0.000826	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—H2AFZ—testicular cancer	1.42e-05	0.000826	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—H2AFZ—testicular cancer	1.42e-05	0.000825	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—STK11—testicular cancer	1.41e-05	0.000821	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—STK11—testicular cancer	1.41e-05	0.00082	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	1.41e-05	0.000819	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—STK11—testicular cancer	1.4e-05	0.000815	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	1.38e-05	0.000802	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—STK11—testicular cancer	1.37e-05	0.000798	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—H2AFZ—testicular cancer	1.36e-05	0.000789	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—HPGDS—testicular cancer	1.35e-05	0.000786	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—STK11—testicular cancer	1.35e-05	0.000785	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—H2AFZ—testicular cancer	1.34e-05	0.000779	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—STK11—testicular cancer	1.33e-05	0.000774	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KITLG—testicular cancer	1.31e-05	0.000759	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KITLG—testicular cancer	1.31e-05	0.000759	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—KIT—testicular cancer	1.31e-05	0.000759	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KITLG—testicular cancer	1.3e-05	0.000754	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—H2AFZ—testicular cancer	1.28e-05	0.000746	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—STK11—testicular cancer	1.28e-05	0.000741	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KITLG—testicular cancer	1.27e-05	0.000738	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—FGFR3—testicular cancer	1.26e-05	0.000731	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KITLG—testicular cancer	1.25e-05	0.000726	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—STK11—testicular cancer	1.25e-05	0.000724	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—HPGDS—testicular cancer	1.24e-05	0.00072	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KITLG—testicular cancer	1.23e-05	0.000716	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—H2AFZ—testicular cancer	1.22e-05	0.000711	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—STK11—testicular cancer	1.22e-05	0.000707	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—STK11—testicular cancer	1.21e-05	0.000703	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—H2AFZ—testicular cancer	1.21e-05	0.000701	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—STK11—testicular cancer	1.2e-05	0.000697	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KITLG—testicular cancer	1.18e-05	0.000686	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—KIT—testicular cancer	1.16e-05	0.000671	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KITLG—testicular cancer	1.13e-05	0.000654	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KITLG—testicular cancer	1.11e-05	0.000645	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	1.09e-05	0.000633	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STK11—testicular cancer	1.08e-05	0.000629	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—STK11—testicular cancer	1.07e-05	0.000622	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	1.05e-05	0.000611	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	1.05e-05	0.000608	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STK11—testicular cancer	1.05e-05	0.000608	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STK11—testicular cancer	1.04e-05	0.000604	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	1.02e-05	0.000591	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STK11—testicular cancer	1.01e-05	0.000588	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KITLG—testicular cancer	1e-05	0.000582	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	1e-05	0.000582	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STK11—testicular cancer	9.96e-06	0.000579	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—STK11—testicular cancer	9.83e-06	0.000571	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—FGFR3—testicular cancer	9.72e-06	0.000564	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—FGFR3—testicular cancer	9.71e-06	0.000564	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KITLG—testicular cancer	9.68e-06	0.000562	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—FGFR3—testicular cancer	9.64e-06	0.00056	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KITLG—testicular cancer	9.63e-06	0.000559	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—FGFR3—testicular cancer	9.44e-06	0.000548	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KITLG—testicular cancer	9.37e-06	0.000544	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—FGFR3—testicular cancer	9.29e-06	0.00054	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—H2AFZ—testicular cancer	9.24e-06	0.000537	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KITLG—testicular cancer	9.22e-06	0.000535	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STK11—testicular cancer	9.18e-06	0.000533	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—FGFR3—testicular cancer	9.17e-06	0.000532	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	9.09e-06	0.000528	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—H2AFZ—testicular cancer	9.07e-06	0.000527	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	9.04e-06	0.000525	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STK11—testicular cancer	9.04e-06	0.000525	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STK11—testicular cancer	9.02e-06	0.000524	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—H2AFZ—testicular cancer	9.01e-06	0.000523	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—STK11—testicular cancer	9.01e-06	0.000523	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STK11—testicular cancer	8.99e-06	0.000522	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STK11—testicular cancer	8.96e-06	0.00052	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	8.92e-06	0.000518	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KIT—testicular cancer	8.92e-06	0.000518	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KIT—testicular cancer	8.91e-06	0.000518	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	8.9e-06	0.000517	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STK11—testicular cancer	8.87e-06	0.000515	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KIT—testicular cancer	8.85e-06	0.000514	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STK11—testicular cancer	8.85e-06	0.000514	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—HPGDS—testicular cancer	8.82e-06	0.000512	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—FGFR3—testicular cancer	8.78e-06	0.00051	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KIT—testicular cancer	8.67e-06	0.000504	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KIT—testicular cancer	8.53e-06	0.000496	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KITLG—testicular cancer	8.5e-06	0.000494	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KIT—testicular cancer	8.42e-06	0.000489	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—FGFR3—testicular cancer	8.37e-06	0.000486	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KITLG—testicular cancer	8.36e-06	0.000486	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KITLG—testicular cancer	8.34e-06	0.000485	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KITLG—testicular cancer	8.32e-06	0.000483	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KITLG—testicular cancer	8.29e-06	0.000482	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	8.27e-06	0.00048	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—FGFR3—testicular cancer	8.25e-06	0.000479	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STK11—testicular cancer	8.22e-06	0.000478	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KITLG—testicular cancer	8.21e-06	0.000477	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KITLG—testicular cancer	8.19e-06	0.000476	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KIT—testicular cancer	8.06e-06	0.000468	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KIT—testicular cancer	7.68e-06	0.000446	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KITLG—testicular cancer	7.61e-06	0.000442	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KIT—testicular cancer	7.58e-06	0.00044	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—HPGDS—testicular cancer	7.47e-06	0.000434	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	7.45e-06	0.000433	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—FGFR3—testicular cancer	7.19e-06	0.000418	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—FGFR3—testicular cancer	7.16e-06	0.000416	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	6.96e-06	0.000404	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	6.85e-06	0.000398	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KIT—testicular cancer	6.84e-06	0.000397	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KIT—testicular cancer	6.6e-06	0.000384	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KIT—testicular cancer	6.57e-06	0.000382	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—STK11—testicular cancer	6.41e-06	0.000372	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KIT—testicular cancer	6.39e-06	0.000371	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—FGFR3—testicular cancer	6.32e-06	0.000367	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KIT—testicular cancer	6.29e-06	0.000365	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—FGFR3—testicular cancer	6.21e-06	0.000361	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—FGFR3—testicular cancer	6.2e-06	0.00036	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—FGFR3—testicular cancer	6.18e-06	0.000359	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—FGFR3—testicular cancer	6.16e-06	0.000358	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—FGFR3—testicular cancer	6.1e-06	0.000354	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	6.09e-06	0.000353	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KIT—testicular cancer	5.8e-06	0.000337	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—HPGDS—testicular cancer	5.77e-06	0.000335	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KIT—testicular cancer	5.71e-06	0.000331	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KIT—testicular cancer	5.69e-06	0.000331	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KIT—testicular cancer	5.68e-06	0.00033	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KIT—testicular cancer	5.66e-06	0.000329	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	5.65e-06	0.000328	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KIT—testicular cancer	5.6e-06	0.000325	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KIT—testicular cancer	5.59e-06	0.000324	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—STK11—testicular cancer	5.43e-06	0.000315	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KIT—testicular cancer	5.19e-06	0.000302	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—STK11—testicular cancer	4.19e-06	0.000243	CbGpPWpGaD
